Avenue Therapeutics Inc (NASDAQ:ATXI)’s Stock Is Buy After Less Market Selling

November 10, 2018 - By Winifred Garcia

The stock of Avenue Therapeutics Inc (NASDAQ:ATXI) registered a decrease of 51.15% in short interest. ATXI’s total short interest was 12,700 shares in November as published by FINRA. Its down 51.15% from 26,000 shares, reported previously. With 6,000 shares average volume, it will take short sellers 2 days to cover their ATXI’s short positions. The short interest to Avenue Therapeutics Inc’s float is 0.22%.

The stock increased 1.21% or $0.05 during the last trading session, reaching $4.19. About 24,444 shares traded. Avenue Therapeutics, Inc. (NASDAQ:ATXI) has declined 45.48% since November 10, 2017 and is downtrending. It has underperformed by 61.10% the S&P500.

Avenue Therapeutics, Inc., a specialty pharmaceutical company, acquires, licenses, develops, and commercializes an intravenous formulation of tramadol HCI principally for use in the acute/intensive care hospital setting. The company has market cap of $44.22 million. The Company’s product candidate is IV Tramadol for the treatment of post-operative pain. It currently has negative earnings. The firm was founded in 2015 and is based in New York, New York.

More notable recent Avenue Therapeutics, Inc. (NASDAQ:ATXI) news were published by: Benzinga.com which released: “44 Biggest Movers From Yesterday” on October 15, 2018, also Benzinga.com with their article: “41 Stocks Moving In Friday’s Mid-Day Session” published on October 12, 2018, Benzinga.com published: “50 Biggest Movers From Yesterday” on October 19, 2018. More interesting news about Avenue Therapeutics, Inc. (NASDAQ:ATXI) were released by: Seekingalpha.com and their article: “Weekly market movement wrap” published on October 13, 2018 as well as Benzinga.com‘s news article titled: “20 Stocks Moving In Friday’s Pre-Market Session” with publication date: October 12, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.


Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter: